Nova Eye Medical (ELXMF) AI Stock Analysis

Company Guidance

Nova Eye guided FY‑27 revenue (ex‑China) of USD 26.0–31.0 million (implying 15–37% growth versus FY‑26’s USD 23.7M, which was up 26% YoY and represents roughly a 26% CAGR since FY‑22’s USD 9.3M), reiterated it delivered EBITDA‑positive results in H2 FY‑26 and expects to be EBITDA‑positive for FY‑27 (no EBITDA figure given), and said July trading was running about 30% above prior run‑rate. Management highlighted the U.S. as the growth engine (U.S. revenue c. USD 18.6M, ~79% of sales, up ~30% YoY and +21% QoQ in the last quarter), ~20,000 procedures/year using the device (~4%–5% share of the ~30k–35k U.S. procedures per month), annualized revenue per rep ~USD 1.9M, and confirmed 2027 reimbursement drafts (~USD 542 surgeon / ~USD 2,204 facility) were broadly in line with 2026. They also noted China is a nascent market (down ~18% to roughly USD 200k), operating‑leverage improvements (sales & marketing OpEx fell from 76% to 52% of sales over time; corporate costs down from ~USD 1.7M to ~1.3M), and that current liquidity is sufficient to fund the FY‑27 plan (described as an unprecedented ~18 quarters of cash cover).